1. Oct 14, 2015. 12 Lead ECG
2. Oct 14, 2015. CA19-9. 20099W
Analyte |
Value |
Flag |
Reference |
Status |
CA 19-9 |
27 U/ML |
|
|
Final |
CA 19-9 |
|
|
|
Final |
Notes: Reference range: <34
SEE COMMENT
This test was performed using the Siemens chemiluminescent
method. Values obtained from different assay methods
cannot be used interchangeably. CA 19-9 levels, regardless
of value, should not be interpreted as absolute evidence of
the presence or absence of disease.
Test Performed at:
Quest Diagnostics
One Malcolm Avenue
Teterboro, NJ 07608
Lawrence Tsao, M.D.
|
3. Oct 14, 2015 CEA
Analyte |
Value |
Flag |
Reference |
Status |
CEA |
4.2 NG/ML |
H |
<3.0 |
Final |
4. Oct 14, 2015. TOTAL LDH
Analyte |
Value |
Flag |
Reference |
Status |
TOTAL LDH |
590 U/L |
|
313-618 |
Final |
5. Oct 14, 2015. HBA1C W EAG
Analyte |
Value |
Flag |
Reference |
Status |
EST. AVG. GLUCOSE |
169 MG/DL |
|
|
Final |
HEMOGLOBIN A1C |
7.5 % |
H |
<6.5 |
Final |
HEMOGLOBIN A1C |
|
|
|
Final |
Notes:
ADA RECOMMENDATIONS:
DIAGNOSIS: 5.7-6.4% PREDIABETIC
=OR>6.5% TYPE 2 DIABETIC
DIABETIC CONTROL: <7.0% PROPERLY MANAGED
GLYCOHEMOGLOBIN ASSAYS SHOULD BE PERFORMED AT LEAST TWICE YEARLY FOR THE
PATIENT WHO HAS STABLE GLYCEMIC CONTROL.
|
6. Oct 14, 2015 FERRITIN
Analyte |
Value |
Flag |
Reference |
Status |
FERRITIN |
354.0 NG/ML |
|
17.9-464 |
Final |
7. Oct 14, 2015 MISYS EHMC
Analyte |
Value |
Flag |
Reference |
Status |
ALBUMIN |
4.0 G/DL |
|
3.5-5.0 |
Final |
ALK PHOS |
87 U/L |
|
38-126 |
Final |
ALT |
28 U/L |
|
21-72 |
Final |
ANION GAP W/ K |
15 MMOL/L |
|
9-18 |
Final |
AST |
22 U/L |
|
17-59 |
Final |
BILIRUBIN,TOTAL |
0.6 MG/DL |
|
0.2-1.3 |
Final |
BUN |
25 MG/DL |
H |
9-20 |
Final |
CALCIUM |
9.0 MG/DL |
|
8.4-10.2 |
Final |
CHLORIDE |
102 MMOL/L |
|
98-107 |
Final |
CO2 |
25 MMOL/L |
|
22-30 |
Final |
CREATININE |
1.4 MG/DL |
H |
0.7-1.3 |
Final |
GFR, EST. BY MDRD |
52.0 ML/MIN/1.73M SQ |
L |
>60 |
Final |
GLUCOSE |
230 MG/DL |
H |
74-106 |
Final |
GLUCOSE |
|
|
|
Final |
Notes: (AMERICAN DIABETES ASSOCIATION RECOMMENDATION)
FASTING GLUCOSE
<100 NORMAL
100-125 PREDIABETIC
126 OR HIGHER DIABETIC
|
POTASSIUM |
4.4 MMOL/L |
|
3.5-5.1 |
Final |
SODIUM |
138 MMOL/L |
|
137-145 |
Final |
TOTAL PROTEIN |
6.9 G/DL |
|
6.3-8.2 |
Final |
GFR COMMENT |
|
|
|
Final |
Notes: IF PATIENT IS OF AFRICAN DESCENT, MULTIPLY ESTIMATED GFR BY 1.21.
|
8.Oct 14, 2015 TYPE & SCREEN (XM CONVERTIBLE)
Analyte |
Value |
Flag |
Reference |
Status |
TYPE & SCREEN (XM CONVERTIBLE) |
|
|
|
Final |
Notes: CROSSMATCH EXPIRATION:10/22/2015
|
TYPE & SCREEN (XM CONVERTIBLE) |
|
|
|
Final |
Notes: ABO/RH(D):O NEGATIVE
ANTIBODY SCREEN:NEGATIVE
|
TYPE & SCREEN (XM CONVERTIBLE) |
|
|
|
Final |
Notes: BLOOD COMPONENT TYPE:RED CELLS
|
TYPE & SCREEN (XM CONVERTIBLE) |
UNITS ORDERED:0 |
|
|
Final |
9. Oct 14, 2015 IRON PANEL
Analyte |
Value |
Flag |
Reference |
Status |
TSI |
18 % |
|
15-50 |
Final |
IRON |
46 UG/DL |
L |
49-181 |
Final |
TIBC |
261 UG/DL |
10. Oct 14, 2015 PTPTT
Analyte |
Value |
Flag |
Reference |
Status |
INR |
1.0 |
|
0.9-1.1 |
Final |
INR |
|
|
|
Final |
Notes: *LEVEL OF THERAPY*
2.0-3.0 DEEP VEIN THROMBOSIS, PULMONARY EMBOLISM,
ATRIAL FIBRILLATION, PREVENTION OF
SYST.EMBOLI IN VALVULAR HEART DISEASE,
ACUTE MYOCARDIAL INFARCTION.
2.5-3.5 PREVENTION OF SYSTEMIC EMBOLISM
WITH MECHANICAL HEART VALVES.
3.0-4.0 ANTIPHOSPHOLIPID ANTIBODY SYNDROME.
3.0-4.5 PREVENTION OF SYSTEMIC EMBOLISM IN
HIGH RISK PATIENTS WITH MECHANICAL
MITRAL OR AORTIC VALVES,
RECURRENT SYSTEMIC EMBOLISM.
|
PT |
13.1 SECS |
|
11.8-14.8 |
Final |
PT |
|
|
|
Final |
Notes: PLEASE NOTE NEW REFERENCE RANGE
|
PTT |
33 SECS |
|
24-38 |
Final |
Provider Comments: This result has been automatically released to your health record at the direction of your provider. Your provider may not have yet reviewed this result.
11. Oct 14, 2015 DIFFERENTIAL
Analyte |
Value |
Flag |
Reference |
Status |
BASO |
0.2 % |
|
0.0-1.5 |
Final |
BASO ABSOLUTE |
0.0 K/UL |
|
0.0-0.2 |
Final |
DIFF TYPE |
|
|
|
Final |
Notes: AUTOMATED DIFF
|
EO |
0.9 % |
|
0.1-4.5 |
Final |
EO ABSOLUTE |
0.1 K/UL |
|
0.0-0.5 |
Final |
LYMPH |
8.3 % |
L |
19.4-45.4 |
Final |
LYMPH ABSOLUTE |
0.7 K/UL |
L |
1.2-3.4 |
Final |
MONO |
5.9 % |
|
1.6-11.3 |
Final |
MONO ABSOLUTE |
0.5 K/UL |
|
0.0-0.8 |
Final |
NEUTRO |
84.7 % |
H |
44.1-69.7 |
Final |
NEUTRO ABSOLUTE |
7.3 K/UL |
|
1.8-7.7 |
Final |
Provider Comments: This result has been automatically released to your health record at the direction of your provider. Your provider may not have yet reviewed this result.
12. Oct 14, 2015 CBC WITH DIFF BATTERY
Analyte |
Value |
Flag |
Reference |
Status |
HCT |
32.8 % |
L |
35.0-47.0 |
Final |
HGB |
11.4 G/DL |
L |
13.5-18.0 |
Final |
MCH |
31.1 PG |
|
26.0-34.0 |
Final |
MCHC |
34.8 G/DL |
|
32.0-36.0 |
Final |
MCV |
89.3 FL |
|
81.8-97.8 |
Final |
PLT |
213 K/UL |
|
140.0-400.0 |
Final |
RBC |
3.67 M/UL |
L |
4.00-5.70 |
Final |
RDW |
13.7 % |
|
10.0-15.2 |
Final |
WBC |
8.6 K/UL |
|
4.5-11.0 |
Final |
Provider Comments: This result has been automatically released to your health record at the direction of your provider. Your provider may not have yet reviewed this result